Abstract 231P
Background
Body mass index (BMI) has shown the associated with clinical outcomes of immune checkpoint inhibitors (ICIs) treatment in patients with several malignancies. We previously reported the association between clinical outcome in advanced urothelial carcinoma (UC) patients treated with pembrolizumab and BMI according to the WHO international classification. However, no patient in our cohort was grouped into obese (BMI 30kg/m2≤) and WHO BMI classification may be unsuitable for Asians. Therefore, we investigated the association between BMI classification developed for Asian people and clinical outcomes of pembrolizumab for advanced UC.
Methods
We retrospectively reviewed consecutive patients with advanced UC who received pembrolizumab between December 2003 and March 2023. Patients were divided into three groups based on BMI classification for Asians; the non-overweight group (BMI < 22.9 kg/m2), the overweight group (23 ≤ BMI < 24.9 kg/m2), and the obese group (BMI ≥ 25 kg/m2). Tumor response, progression-free survival (PFS), overall survival (OS), and incidence of adverse events (AEs) were compared among the groups. We additionally investigated factors associated with PFS using the multivariate analysis.
Results
Of 99 eligible patients, 54 (54.5%), 21 (21.2%) and 24 (24.2%) were in the non-overweight, overweight and obese group, respectively. PFS was significantly longer in the obese group (median 10.3 months) than that in the non-overweight (median 4.2 months) and the overweight group (median 2.3 months) (p=0.04). Multivariate analysis showed that obese was significantly associated with favorable PFS. The obese group had higher objective response rate and longer OS compared to other groups, although the difference did not reach the statistical significance. Multivariate analysis showed that obese was significantly associated with favorable PFS. There was no difference in the occurrence of irAEs among three groups.
Conclusions
BMI was associated with PFS for patients with advanced UC received pembrolizumab and BMI Asian classification may be more useful and suitable for Asian patients than that of WHO classification.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
173P - Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
174P - Unlocking the potential of blood-based biomarkers in pancreatic cancer for early detection and therapeutic screening
Presenter: Belinda Lee
Session: Poster Display
Resources:
Abstract
175P - Genomic evolution of peritoneal metastasis in gastric adenocarcinoma
Presenter: Lan Tu
Session: Poster Display
Resources:
Abstract
176P - Identification of novel diagnostic markers for pancreatic neuroendocrine tumors by proteomics with patient blood
Presenter: HEE SEON Kim
Session: Poster Display
Resources:
Abstract
177P - Burden of stomach cancer attributable to smoking in South Asia from 1990-2019, its projection of deaths to 2040: A benchmarking and comparative analysis
Presenter: Pranay Vaghela
Session: Poster Display
Resources:
Abstract
178P - Survival benefit of splenic hilar lymph nodes (no.10) dissection in B4 type gastric carcinoma: An IPTW propensity score analysis of large multi-institutional data
Presenter: Oh Jeong
Session: Poster Display
Resources:
Abstract
179P - The impact of pre-operative nutritional/rehabilitative assessments and support on postoperative outcomes in very elderly gastric cancer patients
Presenter: Yuki Ushimaru
Session: Poster Display
Resources:
Abstract
180P - Appraisal of surgical outcomes and oncological efficiency of intraoperative adverse events in robotic radical gastrectomy for gastric cancer
Presenter: shangguan Zhixin
Session: Poster Display
Resources:
Abstract
181P - TQB2450 (PD-L1 blockade) in combination with anlotinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: Primary results from a prospective, single-arm, phase Ib study
Presenter: Zhen Huang
Session: Poster Display
Resources:
Abstract
182P - Cytoreductive surgery and chemotherapy in metastatic gastric adenocarcinoma: A population-based study
Presenter: Dana Al Zamer
Session: Poster Display
Resources:
Abstract